It has been approved as the first and only aldosterone synthase inhibitor treatment for adults with hypertension.

The company is part of a new EU‑funded consortium developing an AI‑ and robotics‑driven manufacturing platform to secure access to critical medicines during shortages and supply chain disruptions.

The Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS smallpox vaccine.

Bactiguard Holding has announced an update to its long standing collaboration with license partner BD (Becton, Dickinson & Company) through the signing of a restated long-term agreement.

When Encare was awarded the Swecare Export Award 2026, the company was highlighted as one of the Swedish healthtech companies that has succeeded in translating clinical research into concrete benefits in healthcare internationally.

Gradientech has received a Notice of Allowance in the United States for its single-use microfluidic test, a key component of the CE marked QuickMIC system.

BioArctic’s partner Eisai has announced that the FDA has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi Iqlik, as a starting dose for the treatment of early Alzheimer’s disease.

Oncopeptides has announced its intention to submit a Type II variation application to the European Medicines Agency (EMA).

Diamyd Medical has announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed.

Professor Charlotte Ling of Lund University in Sweden has fundamentally changed the scientific understanding of type 2 diabetes by showing that the disease arises through an interplay between genes and environmental influences that alter which genes are active.

Through a donation, a new foundation has been formed called Familjen Landegrens stiftelse för medicinsk forskning (Landegren Family Foundation for Medical Research). The purpose of this foundation is to support Uppsala University’s medical research and medical innovation.

For a long time, restoring vision has been like a search for the holy grail for scientists. And for many patients, being diagnosed with a severe retinal disease has meant progressive, irreversible vision loss. However, the past decade has seen some  of the clearest evidence so far that vision loss can be partially restored, not just preserved.